Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
China Pharmacy ; (12): 368-373, 2024.
Artículo en Chino | WPRIM | ID: wpr-1006625

RESUMEN

OBJECTIVE To design pharmaceutical care pathway for the problems related to chemotherapy, and to evaluate whether it contributes to the detection and intervention of drug-related problems (DRPs) in chemotherapy patients. METHODS The pharmaceutical care pathway table and flow charts were constructed and implemented by pharmaceutical care practice experience. The patients who were admitted to our hospital for chemotherapy before and after the implementation of the pharmaceutical care pathway were divided into control group (before the implementation,60 cases) and observation group (after the implementation,64 cases), respectively; the relevant medical records of patients in the control group were extracted to evaluate DRPs, and pharmaceutical care of chemotherapy-related problems was performed for patients in observation group to extract DRPs. The basic condition, chemotherapy condition, DRPs classification and intervention status, adverse reactions induced by chemotherapy, PCNE classification of DRPs, occurrence time of DRPs, and drug classes related to DRPs were compared between 2 groups. RESULTS There was no statistical significance in the basic situation, chemotherapy regimen and chemotherapy drug category between the two groups (P>0.05). DRPs occurred in 46 and 37 patients in control group and observation group, respectively. In both groups, DRPs mainly occurred during chemotherapy, and mainly in the early stage of chemotherapy. Using the new pathway, the detection of DRPs significantly increased from 52.17% in the control group to 91.89% in the observation group (P<0.05). The successful intervention rate of DRPs was significantly increased from 32.61% in the control group to 72.97% in the observation group (P< 0.05). The incidence of adverse drug reactions significantly decreased from 28.33% in the control group to 12.50% in the observation group(P<0.05). The main problem type of DRPs in the control group was treatment effectiveness, which mainly involved adjuvant antitumor drugs, mainly due to the use of adjuvant anti-tumor drugs for off-label prescribing; that of the observation group was treatment effectiveness and treatment safety, which mainly involved vomiting drugs, mainly due to insufficient medication to prevent nausea and vomiting caused by chemotherapy. CONCLUSIONS The implementation of the pathway helps clinical pharmacists to detect and intervene in DRPs among chemotherapy patients, and reduces the occurrence of chemotherapy-induced adverse reactions.

2.
China Pharmacy ; (12): 2162-2166, 2022.
Artículo en Chino | WPRIM | ID: wpr-941462

RESUMEN

OBJECTIV E To develop the infor mation-based pharmaceutical care pathway of anticoagulant therapy in patients with atrial fibrillation and improve the efficacy and safety of treatment for them. METHODS The“anticoagulant pharmaceutical care”module was developed on the basis of medical intelligent and decision system. Patients with atrial fibrillation were taken pharmaceutical care in the whole anticoagulant treatment by evaluating the thromboembolism and bleeding risks ,pre-reviewing antithrombotic prescriptions ,monitoring efficacy and drug interactions ,and warning adverse reactions. RESULTS A total of 1 228 patients receiving anticoagulant therapy were enrolled. It was found after analysis of their doctor ’s orders that 9.27% of the patients adjusted the improper antithrombotic therapies ,3.99% modulated treatments according to the effects of potential drug interactions or the risk of adverse reactions ,and 70.29% of the wrong prescriptions were intervened successfully. After the information-based pharmaceutical care ,the anticoagulation treatment rate increased from 88.73% to 97.40%,the rate of patients ’achievements to warfarin’s international normalized ratio in hospital increased from 38.64% to 66.67%,and the incidence of serious bleeding events decreased from 2.94% to 0.37% (P<0.05). CONCLUSIONS The information-based pharmaceutical care path of anticoagulant therapy achieved comprehensive ,efficient and accurate management of patients with atrial fibrillation ,and improved the rationality ,effectiveness and safety of anticoagulant therapy.

3.
China Pharmacy ; (12): 5017-5020, 2016.
Artículo en Chino | WPRIM | ID: wpr-506199

RESUMEN

OBJECTIVE:To provide the new idea for clinical pharmacists providing pharmaceutical care in oncology depart-ment. METHODS:Applying the principles and methods of clinical pathway,the pharmaceutical care of anti-tumor drugs could be divided into before medication,during medication,after medication and patient education,according to the sequence of taking med-icine. On the basis of evidence-based medicine,the care contents of each unit were established,and the pharmaceutical care path-way (PCP) was formed. During chemotherapy duration for a breast cancer metastasis patient with liver function injury,clinical pharmacists conducted pharmaceutical care for drug pretreatment,ADR monitoring and disposal,patient education,as well as put forward the proposal of drug treatment as supplementing calcium,adjusting the dose of epirubicin and paclitaxel targeting on PCP of zoledronic acid,epirubicin and paclitaxel. RESULTS:Physicians adopted the pharmacist’s recommendations. The patient suf-fered from joint and muscle pain during chemotherapy,and the symptom was relieved after symptomatic treatment by celecoxib;chest and back discomfort was relieved significantly after chemotherapy,and the disease condition kept stable. The patient was dis-charged from the hospital. CONCLUSIONS:PCP focus on the time,content and countermeasures of pharmaceutical care,the pro-gram and treatment results of pharmaceutical care,and promote standardization,formalization,simplification and procedure of pharmaceutical care. Clinical pharmacists conduct individualized pharmaceutical care rapidly targeting on PCP so as to deepen the communication of clinical pharmacists with physicians,nurses and patients,and promote the development of pharmaceutical care smoothly.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA